KR970706817A - 2-[n-(1,2-벤즈이소티아조일-3(2h)온-1,1-디옥사이드] 에틸의 5-에톡시카르보닐-2,4,6-트리메틸-1,4-디히드로피리딘-3-카르복실레이트의 신규한 용도(new applications of 5-ethoxycarbonyl-2,4,6-trimethyl-1,4-dihydropyridine-3-carboxylate of 2-〔1,2-benzisothiazolyl-3(2h)one-1,1-dioxide〕ethyl - Google Patents

2-[n-(1,2-벤즈이소티아조일-3(2h)온-1,1-디옥사이드] 에틸의 5-에톡시카르보닐-2,4,6-트리메틸-1,4-디히드로피리딘-3-카르복실레이트의 신규한 용도(new applications of 5-ethoxycarbonyl-2,4,6-trimethyl-1,4-dihydropyridine-3-carboxylate of 2-〔1,2-benzisothiazolyl-3(2h)one-1,1-dioxide〕ethyl

Info

Publication number
KR970706817A
KR970706817A KR1019970702829A KR19970702829A KR970706817A KR 970706817 A KR970706817 A KR 970706817A KR 1019970702829 A KR1019970702829 A KR 1019970702829A KR 19970702829 A KR19970702829 A KR 19970702829A KR 970706817 A KR970706817 A KR 970706817A
Authority
KR
South Korea
Prior art keywords
carboxylate
trimethyl
dihydropyridine
ethoxycarbonyl
preparation
Prior art date
Application number
KR1019970702829A
Other languages
English (en)
Inventor
까를로스 순켈 레떼리에르
프란씨스코 하비에르 씨에로 꼬랄
미겔 파우 데 까사후아나 무뇨스
삘라르 오르떼가 나바레떼
하이메 쁘리에고 페르난데스 델 깜뽀
루이스 산또스 힐
Original Assignee
알론소 아벤띤, 안또니오
라보라또리오스 알떼르, 에세. 아.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 알론소 아벤띤, 안또니오, 라보라또리오스 알떼르, 에세. 아. filed Critical 알론소 아벤띤, 안또니오
Publication of KR970706817A publication Critical patent/KR970706817A/ko

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

본 발명은 질병에 의한 혈관 폐색위험성이 높고 죽상동맥경화증 및/또는 재발협착증을 앓고 있는 환자를 치료하기 위한 치료약으로서 상기한 생성물을 용도가 상세하게 개시되어 있다. 상기한 물질은 혈관의 재발협착증을 방지하고 아테롬성 손상을 감소시키기 위해서 죽상동맥경화성 질환을 가진 환자에게 다른 약과 함께 또는 단독으로 경구 또는 비경구적인 방법으로 복용할 수 있다.

Description

2-〔N-(1, 2-벤즈이소티아조일-3(2H)온-1,1-디옥사이드〕에틸의 5-에톡시카르보닐-2, 4, 6-트리메틸-1, 4-디히드로피리딘-3-카르복실레이트의 신규한 용도(NEW APPLICATIONS OF 5-ETHOXYCARBONYL-2, 4, 6-TRIMETHYL-1, 4- DIHYDROPYRIDINE-3-CARBOXYLATE OF 2-〔1,2-BENZISOTHIAZOLYL-3(2H)ONE-1, 1- DIOXIDE〕ETHYL
본 내용은 요부공개 건이므로 전문내용을 수록하지 않았음

Claims (14)

  1. 동맥경화에 효과가 있는 약제로서 2-〔N-(1, 2-벤즈이소티아조일-3(2H)온-1,1-디옥사이드〕에틸의 5-에톡시카르보닐-2, 4, 6-트리메틸-1, 4-디히드로피리딘-3-카르복실레이트의 용도.
  2. 허혈성 및 폐색혈관질환에 효과가 있는 약제로서 2-〔N-(1, 2-벤즈이소티아조일-3(2H)온-1,1-디옥사이드〕에틸의 5-에톡시카르보닐-2, 4, 6-트리메틸-1, 4-디히드로피리딘-3-카르복실레이트의 용도.
  3. 세포증식의 저해효과가 있는 약제로서 2-〔N-(1, 2-벤즈이소티아조일-3(2H)온-1,1-디옥사이드〕에틸의 5-에톡시카르보닐-2, 4, 6-트리메틸-1, 4-디히드로피리딘-3-카르복실레이트의 용도.
  4. 세포전달을 정상화시키는 효과가 있는 약제로서 2-〔N-(1, 2-벤즈이소티아조일-3(2H)온-1,1-디옥사이드〕에틸의 5-에톡시카르보닐-2, 4, 6-트리메틸-1, 4-디히드로피리딘-3-카르복실레이트의 용도.
  5. 제1항 내지 제4항 중 어느 한 항에 있어서, 부정맥 파행증상 환자의 치료에 사용하기 위한 2-〔N-(1, 2-벤즈이소티아조일-3(2H)온-1,1-디옥사이드〕에틸의 5-에톡시카르보닐-2, 4, 6-트리메틸-1, 4-디히드로피리딘-3-카르복실레이트의 용도.
  6. 제1항 내지 제4항 중 어느 한 항에 있어서, 지방에 상관없이 변경된 임상 셋팅으로 동맥 폐색환자의 치료에 사용하기 위한 2-〔N-(1, 2-벤즈이소티아조일-3(2H)온-1,1-디옥사이드〕에틸의 5-에톡시카르보닐-2, 4, 6-트리메틸-1, 4-디히드로피리딘-3-카르복실레이트의 용도.
  7. 동맥경화를 치료하기 위한 약의 조제에 있어서 2-〔N-(1, 2-벤즈이소티아조일-3(2H)온-1,1-디옥사이드〕에틸의 5-에톡시카르보닐-2, 4, 6-트리메틸-1, 4-디히드로피리딘-3-카르복실레이트의 용도.
  8. 허혈성 및 폐색혈관질환을 치료하기 위한 약의 조제에 있어서 2-〔N-(1, 2-벤즈이소티아조일-3(2H)온-1,1-디옥사이드〕에틸의 5-에톡시카르보닐-2, 4, 6-트리메틸-1, 4-디히드로피리딘-3-카르복실레이트의 용도.
  9. 높은 병리상의 세포증식이 나타나는 질환을 치료하기 위한 약의 조제에 있어서 2-〔N-(1, 2-벤즈이소티아조일-3(2H)온-1,1-디옥사이드〕에틸의 5-에톡시카르보닐-2, 4, 6-트리메틸-1, 4-디히드로피리딘-3-카르복실레이트의 용도.
  10. 높은 병리상의 세포 내부전달이 나타나는 질환을 치료하기 위한 약의 조제에 있어서 2-[N-(1,2-벤즈이소티아조일-3(2H)온-1,1-디옥사이드]에틸의 5-에톡시카르보닐-2,4,6-트리메틸-1,4-디히드로피리딘-3-카르복실레이트의 용도.
  11. 부정맥 파행의 치료를 위한 약의 조제에 있어서 2-〔N-(1, 2-벤즈이소티아조일-3(2H)온-1,1-디옥사이드〕에틸의 5-에톡시카르보닐-2, 4, 6-트리메틸-1, 4-디히드로피리딘-3-카르복실레이트의 용도.
  12. 제1항 내지 제11항 중 어느 한 항에 있어서, 활성성분으로서 이 생성물과 약학적으로 수용가능한 부형무 또는 용제를 함유하는 약학적 조성물의 조제에 있어서 2-〔N-(1, 2-벤즈이소티아조일-3(2H)온-1,1-디옥사이드〕에틸의 5-에톡시카르보닐-2, 4, 6-트리메틸-1, 4-디히드로피리딘-3-카르복실레이트의 용도.
  13. 제1항 내지 제12항 중 어느 한 항에 있어서, 상기한 생성물은 β-블록커, 칼슘관 안타고니스트 및 저지질 혈증제와 같은 혈관확장활성이 있는 다른 약제들 등의 혈관활성제와 1종 이상과 결합하거나 또는 단독으로 사용되는 2-〔N-(1, 2-벤즈이소티아조일-3(2H)온-1,1-디옥사이드〕에틸의 5-에톡시카르보닐-2, 4, 6-트리메틸-1, 4-디히드로피리딘-3-카르복실레이트의 용도.
  14. 제1항 내지 제13항 중 어느 한 항에 있어서, 경구 또는 비경구적인 방법으로 복용하기 위한 조제의 제조에 있어서 2-〔N-(1, 2-벤즈이소티아조일-3(2H)온-1,1-디옥사이드〕에틸의 5-에톡시카르보닐-2, 4, 6-트리메틸-1, 4-디히드로피리딘-3-카르복실레이트의 용도.
    ※ 참고사항 : 최초출원 내용에 의하여 공개하는 것임.
KR1019970702829A 1995-08-25 1996-08-20 2-[n-(1,2-벤즈이소티아조일-3(2h)온-1,1-디옥사이드] 에틸의 5-에톡시카르보닐-2,4,6-트리메틸-1,4-디히드로피리딘-3-카르복실레이트의 신규한 용도(new applications of 5-ethoxycarbonyl-2,4,6-trimethyl-1,4-dihydropyridine-3-carboxylate of 2-〔1,2-benzisothiazolyl-3(2h)one-1,1-dioxide〕ethyl KR970706817A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP95500122A EP0771560A1 (en) 1995-08-25 1995-08-25 Use of 2- N-(1,2-benzoisothiazolyl-3(2H)one-1,1-dioxide ethyl 5-ethoxycarbonyl-2,4,6-trimethyl-1,4-dihydropiridine-3-carboxylate in the treatment of vascular disorders
EP95500122.7 1995-08-25
PCT/ES1996/000160 WO1997007801A1 (es) 1995-08-25 1996-08-20 Nuevas aplicaciones del 5-etoxicarbonil-2,4,6-trimetil-1,4-dihidropiridina-3-carboxilato de 2-[n-(1,2-benzisotiazolil-3(2h)ona-1,1-dioxido]etilo

Publications (1)

Publication Number Publication Date
KR970706817A true KR970706817A (ko) 1997-12-01

Family

ID=8221657

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1019970702829A KR970706817A (ko) 1995-08-25 1996-08-20 2-[n-(1,2-벤즈이소티아조일-3(2h)온-1,1-디옥사이드] 에틸의 5-에톡시카르보닐-2,4,6-트리메틸-1,4-디히드로피리딘-3-카르복실레이트의 신규한 용도(new applications of 5-ethoxycarbonyl-2,4,6-trimethyl-1,4-dihydropyridine-3-carboxylate of 2-〔1,2-benzisothiazolyl-3(2h)one-1,1-dioxide〕ethyl

Country Status (12)

Country Link
EP (1) EP0771560A1 (ko)
JP (1) JPH10508879A (ko)
KR (1) KR970706817A (ko)
AU (1) AU6931496A (ko)
BR (1) BR9606691A (ko)
CA (1) CA2203624A1 (ko)
EA (1) EA199700053A1 (ko)
HU (1) HUP9701695A3 (ko)
IL (1) IL120718A0 (ko)
MX (1) MX9703032A (ko)
WO (1) WO1997007801A1 (ko)
ZA (1) ZA967223B (ko)

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3617976A1 (de) * 1986-05-28 1988-01-14 Alter Sa 1,4-dihydropyridin, verfahren zu dessen herstellung und dessen verwendung in antithrombotischen medikamenten

Also Published As

Publication number Publication date
MX9703032A (es) 1997-12-31
IL120718A0 (en) 1997-08-14
CA2203624A1 (en) 1997-03-06
HUP9701695A2 (hu) 1998-03-30
EA199700053A1 (ru) 1997-12-30
JPH10508879A (ja) 1998-09-02
ZA967223B (en) 1997-03-03
BR9606691A (pt) 2000-05-09
AU6931496A (en) 1997-03-19
HUP9701695A3 (en) 1999-10-28
WO1997007801A1 (es) 1997-03-06
EP0771560A1 (en) 1997-05-07

Similar Documents

Publication Publication Date Title
AU725637B2 (en) Reparation and prevention of fibrotic lesions
Ardekian et al. Does low-dose aspirin therapy complicate oral surgical procedures?
US5518729A (en) Compositions and methods for reparation and prevention of fibrotic lesions
AU687816B2 (en) Compositions and methods for reparation and prevention of fibrotic lesions
CA2196174C (en) Use of ketoconazole and related substances in medicaments for treatment of type ii diabetes
WO2005065069A3 (en) Pharmaceutical methods, dosing regimes and dosage forms for the treatment of alzheimer's disease
RU95121731A (ru) Применение рилузола для лечения нейро-спида и способ получения лекарственного средства
JP2001510795A5 (ko)
MXPA02003495A (es) Derivados de piridinio para el manejo de complicaciones vasculares diabeticas y relacionadas con la edad, proceso para su preparacion, y usos terapeuticos de los mismos.
JPS59112948A (ja) コレステロ−ルレベル低下剤
KR880007074A (ko) 의약품
HUP0203303A2 (hu) Készítmény taxánok humán betegeknek történő orális adagolására
EP1161279A1 (en) Treatment of thrombosis by combined use of a factor xa inhibitor and aspirin, tissue plasminogen activator (tpa), a gpiib/iiia antagonist, low molecular weight heparin or heparin
RU2001118854A (ru) Оптически активное производное пиридил-4н-1,2,4-оксадиазина и его применение при лечении сосудистых заболеваний
WO2000024397A1 (fr) Composition de medicament immunomodulateur
KR970706817A (ko) 2-[n-(1,2-벤즈이소티아조일-3(2h)온-1,1-디옥사이드] 에틸의 5-에톡시카르보닐-2,4,6-트리메틸-1,4-디히드로피리딘-3-카르복실레이트의 신규한 용도(new applications of 5-ethoxycarbonyl-2,4,6-trimethyl-1,4-dihydropyridine-3-carboxylate of 2-〔1,2-benzisothiazolyl-3(2h)one-1,1-dioxide〕ethyl
RU2007125976A (ru) Способ уменьшения, стабилизации и предупреждения разрыва богатой липидами бляшки
JPH06172187A (ja) 筋ジストロフィー症治療薬
BR0011714A (pt) Medicamento oftalmológico neuro-protetor e retino-protetor e utilização de um princìpio ativo de medicamento
CN109562179A (zh) N,n-双-2-巯基乙基间苯二甲酰胺的新用途
RU95110494A (ru) Средство с регулируемым высвобождением пентоксифиллина для лечения сосудистых заболеваний
JPH0311022A (ja) 薬剤組成物
JPH04159224A (ja) ヒトの糖尿病性知覚障害および末梢神経障害の治療剤
Markson LIVER AND THIOURACIL
Mant et al. Absence of drug interaction between temafloxacin and low dose heparin

Legal Events

Date Code Title Description
WITN Application deemed withdrawn, e.g. because no request for examination was filed or no examination fee was paid